AVRO AvroBio Inc
- Biological Product (except Diagnostic) Manufacturing
15 minute delayed price. Price provided by IEX Cloud. The content contained therein is being provided to you for informational purposes only, does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and does not constitute a recommendation by GoScour to buy, sell, or hold any security, financial product, or instrument referenced in the content. GoScour is not liable for any errors or delays in content, or for any actions taken in reliance on any content.
AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario.